SEC says pharma execs lied about goat's blood drug
WASHINGTON — Federal regulators are charging four pharmaceutical executives with misleading investors with claims that a drug derived from goat's blood might be approved for human use.
The Securities and Exchange Commission says that the executives told investors they were seeking permission to test the drug on humans in the U.S. and Europe.
The SEC says U.S. health authorities have twice blocked the clinical trials. It says the company never submitted an application in Europe.
The charges are against Immunosyn Corp. CEO Stephen Ferrone, the company's Chief Financial Officer Douglas McClain Jr., Argyle Biotechnologies LLC CEO James Miceli and Chief Scientific Officer Douglas McClain Sr. Argyle is Immunosyn's biggest shareholder.
All but Ferrone also face charges of insider trading for unloading about $20 million worth of stock based on the false statements.
- Share Facebook Twitter
Article sent to (required)E-mail
Article sent from (required)E-mail Name
Subject Line (article title)
Message (optional)Success - Article sent Click to close
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.Need more information about reprints? Visit our Reprints Section for more details.
Contact information ( * required )Name * Company Telephone * E-mail *
Article InformationTitle URL
Message (optional)Success - Reprint request sent Click to close